Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers

NCT03195699 is registered in ClinicalTrials.gov with Tvardi Therapeutics, Incorporated as lead sponsor.

NCT NCT03195699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03195699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers
Lead sponsor
Tvardi Therapeutics, Incorporated
Phase
Phase 1
Overall status
Completed
Start date
November 15, 2017
Completion date
June 24, 2024
Enrollment
64 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, breast cancer, colorectal cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular cancer, melanoma, non small cell lung cancer